Dyadic International, Inc. (DYAI)

Market Cap	37.70M
Revenue (ttm)	2.50M
Net Income (ttm)	-11.80M
Shares Out	28.39M
EPS (ttm)	-0.44
PE Ratio	n/a
Forward PE	13.64
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,279
Open	1.3
Previous Close	1.32
Day's Range	1.27 - 1.31
52-Week Range	1.27 - 4.98
Beta	0.39
Analysts	Buy
Price Target	7.65 (+497.7%)
Earnings Date	Nov 10, 2022

About DYAI

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therape...

• Industry: Biotechnology
• IPO Date: Nov 5, 2004
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: DYAI

Financial Performance

In 2021, DYAI's revenue was $2.40 million, an increase of 50.06% compared to the previous year's $1.60 million. Losses were -$13.07 million, 40.2% more than in 2020.

Analyst Forecast

According to 7 analysts, the average rating for DYAI stock is "Buy." The 12-month stock price forecast is 7.65, which is an increase of 497.66% from the latest price.

Price Target

$7.65

(497.66% upside)

Analyst Consensus: Buy